Domenica Lorusso

2003–2026 年に発表

226
論文数
32,649
被引用数
77
h 指数
201
i10 指数

被引用数

Domenica Lorusso の年別被引用数1994 年: 被引用 2 件2005 年: 被引用 2 件2006 年: 被引用 4 件2007 年: 被引用 5 件2008 年: 被引用 11 件2009 年: 被引用 7 件2010 年: 被引用 18 件2011 年: 被引用 20 件2012 年: 被引用 22 件2013 年: 被引用 22 件2014 年: 被引用 32 件2015 年: 被引用 38 件2016 年: 被引用 59 件2017 年: 被引用 106 件2018 年: 被引用 127 件2019 年: 被引用 659 件2020 年: 被引用 1,101 件2021 年: 被引用 1,179 件2022 年: 被引用 1,377 件2023 年: 被引用 1,455 件2024 年: 被引用 2,696 件2025 年: 被引用 1,430 件2026 年: 被引用 35 件1995〜2004 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,957 件、この内訳の 17.9%中国: 引用元論文 1,201 件、この内訳の 11%イタリア: 引用元論文 1,012 件、この内訳の 9.2%イギリス: 引用元論文 695 件、この内訳の 6.4%フランス: 引用元論文 552 件、この内訳の 5%スペイン: 引用元論文 485 件、この内訳の 4.4%ドイツ: 引用元論文 448 件、この内訳の 4.1%カナダ: 引用元論文 423 件、この内訳の 3.9%日本: 引用元論文 355 件、この内訳の 3.2%オランダ: 引用元論文 294 件、この内訳の 2.7%オーストラリア: 引用元論文 242 件、この内訳の 2.2%ベルギー: 引用元論文 229 件、この内訳の 2.1%
0%17.9%その他 27.9%

分野

  • Medicine79.8%
  • Biochemistry, Genetics and Molecular Biology13.6%
  • Immunology and Microbiology2.5%
  • Materials Science1.3%
  • Engineering0.7%
  • Computer Science0.5%
  • その他1.6%

トピック

  • Ovarian cancer diagnosis and treatment12%
  • Endometrial and Cervical Cancer Treatments9.6%
  • PARP inhibition in cancer therapy9.2%
  • Cancer Immunotherapy and Biomarkers3.6%
  • DNA Repair Mechanisms2.8%
  • BRCA gene mutations in cancer2.3%
  • その他60.5%

共著者

全論文

検索で開く
  1. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 2,262

  2. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 2,040

  3. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2020 被引用: 1,933

  4. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 992

  5. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 被引用: 2,458

  6. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 893

  7. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian ほか 17 名 - The Lancet 2017 被引用: 1,704

  8. Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 414

  9. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , - Annals of Oncology 2022 被引用: 638

  10. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 372

  11. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antonio González-Martı́n, Viola Heinzelmann‐Schwarz, Florence Joly, J.W. Kim, Frédéric Kridelka, Jonathan A. Ledermann, Domenica Lorusso, Sven� Mahner, W. Glenn McCluggage, Iain A. McNeish, Mikio Mikami, Mansoor Raza Mirza, Philippe Morice, Shibani Nicum, Siel Olbrecht, Dearbhaile M. O’Donnell, Patricia Pautier, François Planchamp, Sandro Pignata, Denis Querleu, Isabelle Ray‐Coquard, Alexandros Rodolakis, Jalid Sehouli, Fatih Selçukbırıcık, Cristiana Sessa, Nilanchali Singh, David S.P. Tan, D. Timmerman, Germana Tognon, Jacobus van der Velden, Ignace Vergote, Petronella O. Witteveen, Alain G. Zeimet - Annals of Oncology 2019 被引用: 1,165

  12. Survival with Cemiplimab in Recurrent Cervical Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , George D. Yancopoulos, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin - New England Journal of Medicine 2022 被引用: 427

  13. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , - Annals of Oncology 2023 被引用: 388

  14. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frederik Marmé, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit - Journal of Clinical Oncology 2022 被引用: 384

  15. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet Oncology 2021 被引用: 394

  16. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023*

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2023 被引用: 442

  17. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 339

  18. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarper Toker, Stephen J. O’Keefe, Sandro Pignata, Linda Duska - The Lancet 2024 被引用: 349

  19. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 292

  20. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sophie Abadie‐Lacourtoisie, Claudia Andreetta, Nerea Anzizar, Daiseuke Aoki, Maria-Pilar Barretina-Ginesta, Marco Johannes Battista, Charlotte Béllier, Anne Gry Bentzen, Dominique Berton, Bertrand Billemont, Line Bjørge, Maria Bjurberg, Destin Black, Alessandra Bologna, Elena Ioana Braicu, Cláudia Casanova, Radoslav Chekerov, Annick Chevalier, Juan Cueva, Bastian Czogalla, Nicolas Delanoy, Dominik Denschlag, Oscar Derke, Michael Eichbaum, Takayuki Enomoto, Carmen Esteban, Michel Fabbro, Tanja Fehm, Annamaria Ferrero, Markus C. Fleisch, Anne Floquet, Antonio Frassoldati, Lydia Gaba, Angiolo Gadducci, Yolanda García García, Elena Geuna, Eva Guerra, Lars Hanker, Anne‐Claire Hardy‐Bessard, Philipp Harter, Kosei Hasegawa, Kristina Hellman, Ana Herrero, Felix Hilpert, Dionyssios Katsaros, M. Koegel, Anthoula Koliadi, Jean‐Emmanuel Kurtz, Bjoern Lampe, Andrea Alberto Lissoni, Alain Lortholary, Giorgia Mangili, Laura Mansi, Frederik Marmé, Cara Mathews, William Mina, Shinichiro Minobe, Katherine Moxley, Shoji Nagao, Ornella Nicoletto, Koji Nishino, Hiroshi Nishio, Shin Nishio, Ana Oaknin, Michaela Onstad, Beatriz Pardo, José Alejandro Pérez Fidalgo, Carmela Pisano, Andrés Poveda, Julia Caroline Radosa ほか 21 名 - The Lancet 2023 被引用: 209

  21. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christian Kurzeder, Sigurd Lax, Fabrice Lécuru, Jonathan A. Ledermann, Tally Levy, Domenica Lorusso, Johanna Mäenpää, Christian Marth, Xavier Matías‐Guiu, Philippe Morice, Hans W. Nijman, Remi A. Nout, Melanie Powell, Denis Querleu, Mansoor Raza Mirza, Nicholas Reed, Alexandros Rodolakis, Helga B. Salvesen, Jalid Sehouli, Cristiana Sessa, Alexandra Taylor, Anneke M. Westermann, Alain G. Zeimet - Annals of Oncology 2015 被引用: 1,380

  22. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 236

  23. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José Alejandro Pérez Fidalgo, Sandro Pignata, Pedro T. Ramírez, Isabelle Ray‐Coquard, Ignacio Romero, Giovanni Scambia, Jalid Sehouli, Ronnie Shapira‐Frommer, Sudha Sundar, David S.P. Tan, Çağatay Taşkıran, Willemien J. van Driel, Ignace Vergote, François Planchamp, Cristiana Sessa, Anna Fagotti - Annals of Oncology 2024 被引用: 284

  24. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 600